Charles Livsey, MD
Epilepsy · Englewood, CONPI 1518108117
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Eisai Inc. accounts for 63.3% of it on its own, with 49 other manufacturers making up the rest. Reporting peaked in 2019 at $14,668 and has fallen 98.0% since, to $295 in 2025. Among epilepsy clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 311 payments — averaging $93.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$18K
- SK Life Science, Inc.$2K
- Ceribell, Inc.$1K
- Medtronic$1K
- UCB, Inc.$1K
- Neuropace, Inc.$840
- plus $4K from 44 others
Across 18 payments — averaging $1985.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- SK Life Science, Inc.$26K
- UCB SA$10K
What the payments were for
- Consulting fees$3,62512%
- Speaking & faculty fees$14,08948%
- Travel & lodging$5632%
- Food & beverage$10,75937%
- Education$380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fycompa$17,435
- Rapid Response EEG$1,425
- ACTIVA$711
- Epidiolex$517
- XCOPRI$387
- RNS Neurostimulator Kit$258
- Penumbra Jet 7$148
- Penumbra SMART Coil$148
- Briviact$147
- VNS Therapy$134
- RNS System$124
How this compares
$29,073 in reported general payments places this provider in the 90th percentile of 28 epilepsy providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 57 | $63,073 |
| BriviactBrivaracetam | 12 | $13,977 |
| Lacosamide | 143 | $12,269 |
| Lamotrigine ErLamotrigine | 30 | $9,200 |
| Levetiracetam | 148 | $6,073 |
| Divalproex Sodium ErDivalproex Sodium | 26 | $4,019 |
| Zonisamide | 54 | $2,704 |
| Lamotrigine | 53 | $2,146 |
| Levetiracetam ErLevetiracetam | 37 | $1,985 |
| Oxcarbazepine | 26 | $1,825 |
| Clobazam | 28 | $1,525 |
| Phenobarbital | 46 | $751 |
| Topiramate | 46 | $724 |
| Propranolol Hcl ErPropranolol Hcl | 13 | $515 |
| Phenytoin Sodium Extended | 15 | $470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $1,633 | $63,07357 claims |
| UCB, Inc.Briviact | $1,245 | $13,97712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 28 epilepsy providers in Colorado.
Other epilepsy in Englewood
- Kelly KnuppAurora$39K
- Danielle McDermottDenver$31K
- Scott DemarestAurora$15K
- Chalita AtallahGreenwood Village$9K
- Jacob PellinenAurora$6K
- Steve SavinoffParker$4K
- Jared WoodwardAurora$3K
- Samuel DestefanoLittleton$3K
- Megan AbbottAurora$2K
- Naveed ChaudhryAurora$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.